| Nov 19 |
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
|
| Nov 10 |
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
|
| Nov 7 |
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 7 |
Phathom Pharmaceuticals GAAP EPS of -$1.32 beats by $0.21, revenue of $16.4M beats by $3.99M
|
| Nov 7 |
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 1 |
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%
|
| Oct 28 |
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
|
| Oct 27 |
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
|
| Sep 27 |
Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges
|
